New hope for bile duct cancer: experimental drug nanvuranlat in final testing

NCT ID NCT07265674

Recruiting now Disease control Sponsor: J-Pharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 4 times

Summary

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live longer. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nanvuranlat
What this could lead to: If it works, this could offer a new treatment option for people with advanced biliary tract cancer who have already tried other therapies.
What could go wrong: This is still an experimental drug. It may not work better than current treatments, and side effects are possible. The trial is recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma gallbladder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BILIARY TRACT CANCER BILIARY TRACT CANCER (BTC)

Contacts and locations

Locations

City of Hope (Site 107)
RECRUITING

Duarte, California, 91010, United States
City of Hope - Chicago Cancer Center (Site 128)
RECRUITING

Zion, Illinois, 60099, United States
Comprehensive Cancer Centers of Nevada - Central Valley (Site 124)
RECRUITING

Las Vegas, Nevada, 89169, United States
Fred Hutchinson Cancer Center Clinic (Site 122)
RECRUITING

Seattle, Washington, 98109, United States
James Cancer Hospital and Solove Research Institute (Site 119)
RECRUITING

Columbus, Ohio, 43219, United States
Karmanos Cancer Center (Site 109)
RECRUITING

Detroit, Michigan, 48201, United States
Masonic Cancer Center, University of Minnesota (Site 116)
RECRUITING

Minneapolis, Minnesota, 55455, United States
Memorial Sloan Kettering Cancer Center (Site 108)
RECRUITING

New York, New York, 10065, United States
Mercy Clinic (Site 110)
RECRUITING

Oklahoma City, Oklahoma, 73120, United States
Moffitt Cancer Center Magnolia Campus (Site 123)
RECRUITING

Tampa, Florida, 33612, United States
Norton Cancer Institute (Site 115)
RECRUITING

Louisville, Kentucky, 40127, United States
Ochsner Medical Center (Site 120)
NOT_YET_RECRUITING

New Orleans, Louisiana, 70121, United States
Rosewell Park Comprehensive Cancer Center (Site 114)
NOT_YET_RECRUITING

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey (Site 103)
RECRUITING

New Brunswick, New Jersey, 08901, United States
UCLA Medical Center (Site 117)
NOT_YET_RECRUITING

Santa Monica, California, 90404, United States
University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111)
RECRUITING

Cleveland, Ohio, 44106, United States
University of California at Irvine (Site 101)
RECRUITING

Orange, California, 92868, United States
University of Texas Southwestern Medical Center (Site 104)
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.